1Oremek GM, Sapoutzis N, Kramer W, Bickeboller R, Jonas D.Value of tumor M2 (Tu M2-PK) in patients with renal carcinoma.Anticancer Res 2000; 20:5095-5098.
2Roigas J, Deger S, Schroeder J, Wille A, Turk I, Brux B, Jung K,Schnorr D, Loening SA. Tumor type M2 pyruvate kinase expression in metastatic renal cell carcinoma. Urol Res 2003; 26.
3Roigas J, Schulze G, Raytarowski S, Jung K, Schnorr D, Loenng SA. Tumor M2 pyruvate kinase in renal cell carcinoma. Studies of plasma in patients. Urology A 2000; 39:554-556.
4Schneider J, Velcovsky HG, Morr H, Katz N, Neu K, Eigenbrodt E. Comparison of the tumor markers tumor M2-PK, CEA,CYFRA 21-1, NSE and SCC in the diagnosis of lung cancer.Anticancer Res 2000; 20:5053-5058.
5Schneider J, Neu K, Grimm H, Velcovsky HG, Weisse G,Eigenbrodt E. Tumor M2-pyruvate kinase in lung cancer patients: immunohistochemical detection and disease monitoring. Anticancer Res 2002; 22(1A): 311-318.
6Schneider J, Peltri G, Bitterlich N, Neu K, Velcovsky HG, Morr H, Katz N, Eigenbrodt E. Fuzzy logic-based tumor marker profiles including a new marker tumor M2-PK improved sensitivity to the detection of progression in lung cancer patients.Anticancer Res 2003: 23(2A): 899-906.
7Schneider J, Peltri G, Bitterlich N, Philipp M, Velcovsky HG,Morr H, Katz N, Eigenbrodt E. Fuzzy logic-based tumor marker profiles improved sensitivity of the detection of progression in small-cell lung cancer patients. Clin Exp Med 2003;2:185-191.
8Pottek T, Muller M, Blum T, Hartmann M. Tu-M2-PK in the blood of testicular and cubital veins in men with testicular cancer. Anticancer Res 2000; 20:5029-5033.
9Luftner D, Mesterharm J, Akrivakis C, Geppert R, Petrides PE,Wernecke KD, Possinger K. Tumor type M2 pyruvate kinase expression in advanced breast cancer. Anticancer Res 2000; 20:5077-5082.
10Hoopmann M, Warm M, Mallmann P, Thomas A, Gohring UJ,Schondorf T. Tumor M2 pyruvate kinase-determination in breast cancer patients receiving trastuzumab therapy. Cancer Lett 2002; 187:223-228.
